# CD3D

Source: https://onco.cc/targets/cd3d/  
OnCo record `cd3d` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CD3D (T-cell surface glycoprotein CD3 delta chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Leukaemia and 5 more.

## Summary

Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain.

Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.85, genetic association 0.00, clinical 0.98).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: CD3 delta subunit of T-cell receptor complex; T-cell surface glycoprotein CD3 delta chain; CD3DELTA; CD3-DELTA; T3D
- Tags: cancer-genes-wave
- Symbol: CD3D
- Class: other
- Biology: Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signalling pathways. In addition of this role of signal transduction in T-cell activation, CD3D plays an essential role in thymocyte differentiation. Indeed, participates in correct intracellular TCR-CD3 complex assembly and surface expression. Location: Cell membrane (UniProt). Locus 11q23.3 (HGNC).
- Where found: Non-Hodgkin lymphoma: Open Targets association 0.61 with non-Hodgkin lymphoma (MONDO_0018908); Multiple myeloma: Open Targets association 0.60 with plasma cell myeloma (MONDO_0009693); Leukaemia: Open Targets association 0.58 with leukaemia (MONDO_0005059); Lung cancer: Open Targets association 0.56 with lung cancer (MONDO_0008903); Neuroendocrine tumours: Open Targets association 0.56 with neuroendocrine neoplasm (MONDO_0019496); Diffuse large B-cell lymphoma: Open Targets association 0.58 with diffuse large B-cell lymphoma (MONDO_0018905)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:1673: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1673
- UniProt P04234: https://www.uniprot.org/uniprotkb/P04234/entry
- NCBI Gene 915: https://www.ncbi.nlm.nih.gov/gene/915
- Ensembl ENSG00000167286: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167286

## Connected records

- collections: [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/cd3d.json